{
  "event_id": "4ad45849f4ed",
  "ticker": "SPPI",
  "company_name": "Spectrum Pharmaceuticals",
  "drug_name": "Poziotinib",
  "pdufa_date": "2022-11-24",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:ZENITH20 Phase 2 (NDA submitted 2021)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.931786",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "HER2/EGFR exon 20 NSCLC",
    "source": "websearch:ZENITH20 Phase 2 (NDA submitted 2021)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.931788",
    "error": null
  },
  "generic_name": {
    "status": "not_searched",
    "value": null,
    "source": null,
    "confidence": 0.0,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "_reset_reason": "Was inferred from: comprehensive_mapping",
    "_reset_at": "2026-01-09T23:49:24.204703"
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.092297",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "derived_from_result",
    "confidence": 0.95,
    "tier": 1,
    "searched_sources": [
      "result_field"
    ],
    "last_searched": null,
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:ZENITH20 Phase 2 (NDA submitted 2021)",
    "confidence": 0.7,
    "evidence": [
      "ZENITH20 Phase 2 (NDA submitted 2021)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.931772",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:ZENITH20 Phase 2 (NDA submitted 2021)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.931780",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "HER2 exon 20 ORR 27.8%",
    "source": "websearch:ZENITH20 Phase 2 (NDA submitted 2021)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.931783",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": true,
    "source": "derived_from_crl_reason",
    "confidence": 0.85,
    "tier": 2
  },
  "phase3_study_names": [
    "A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)",
    "A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation",
    "A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors",
    "A Randomized, Phase 3 Study of Poziotinib in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring HER2 Exon 20 Mutations (PINNACLE)"
  ],
  "nct_ids": [
    "NCT03318939",
    "NCT02979821",
    "NCT03066206",
    "NCT05378763"
  ],
  "enrollment": {
    "count": 648,
    "type": "ACTUAL",
    "nct_id": "NCT03318939",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:41.719573"
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "derived_from_crl_context",
    "confidence": 0.7,
    "tier": 2
  },
  "prior_crl_reason": {
    "status": "found",
    "value": "ODAC voted 9-4 against, high adverse event rates (97.8%)",
    "source": "web_search",
    "category": "CLINICAL_DATA",
    "confidence": 0.9,
    "tier": 2
  },
  "is_resubmission": {
    "status": "found",
    "value": 1,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_crl_reason",
    "confidence": 0.85,
    "tier": 2
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "derived_from_crl_reason",
    "confidence": 0.75,
    "tier": 2
  },
  "result": "crl",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:30:58.997228",
  "enriched_at": "2026-01-11T20:17:58.880420",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "1dcffc130794",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": true
  },
  "mechanism_of_action": "HER2/EGFR inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -1143,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.153992",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:28.639005"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:28.639013"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA accelerated review denial is a blow to Spectrumâ€™s poziotinib"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:43.813124",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:50.122872",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:56.519712",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Grants Fast Track Designation to Poziotinib for HER2 exon ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:57.655810",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA rejects Spectrum's lung cancer drug poziotinib"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:58.880408",
    "search_status": "FOUND"
  }
}